SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Figure out how to Consolidate All encompassing Practices with a Degree in Brain research - 24 African Vacationer Locations
- 35 Great Home Remodel Administrations With Green Arrangements In 2024
- 4Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list
- 5A rare whale is having an encouraging season for births. Scientists warn it might still go extinct
- Key Business Regulations to Consider While Arranging Your Independent venture
- The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree
- Glamour Shots once ruled the mall. I went to one of the last ones standing.
- 1st human missions to Mars should hunt for signs of life, report says
- ‘This year nearly broke me as a scientist’ – US researchers reflect on how 2025’s science cuts have changed their lives
- If evolution is real, then why isn’t it happening now? An anthropologist explains that humans actually are still evolving
- Study finds humans were making fire 400,000 years ago, far earlier than once thought
- A Couple of Modest Guitars for 2024
- Eli Lilly weight-loss drug appears to suppress binge-eating signal, small study finds
